Signalling of multiple interleukin (IL)‐17 family cytokines via IL‐17 receptor A drives psoriasis‐related inflammatory pathways
British Journal of Dermatology2021Vol. 185(3), pp. 585–594
Citations Over TimeTop 10% of 2021 papers
Maxim A. X. Tollenaere, Josephine B. Hebsgaard, David Ewald, Paola Lovato, Sandra Garcet, Xuan Li, Steven Pilger, Minna Lund Tiirikainen, M. Bertelsen, James G. Krueger, Hanne Norsgaard
Abstract
Several IL-17 ligands signalling through IL-17RA are overexpressed in psoriasis skin and induce similar psoriasis-related inflammatory pathways demonstrating their relevance in relation to therapeutic intervention in psoriasis.
Related Papers
- Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.(2016)
- → Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3(2022)11 cited
- → Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis(2022)7 cited
- → Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials(2017)22 cited
- → Ixekizumab efficacy and safety in moderate-to-severe genital psoriasis(2018)